SCHEMBL19124992

SCHEMBL19124992

COC(=O)c1cc(Br)cc2c1CCCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.39
NLRP3 Q96P20 1/20 0.38
OPRK1 P41145 8/20 0.38
HSD17B10 Q99714 3/20 0.38
ALDH1A1 P00352 3/20 0.38
KMT2A Q03164 3/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 1/20 0.38
IKBKB O14920 1/20 0.38
USP2 O75604 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
MAPK10 P53779 1/20 0.38
NR4A2 P43354 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30995655 1.00 ACHE (0.39) ACHENLRP3OPRK1HSD17B10ALDH1A1
SCHEMBL30995649 0.82 CA12 (0.46) ACHENLRP3HSD17B10ALDH1A1KMT2A
SCHEMBL7677467 0.82 CA12 (0.46) ACHENLRP3HSD17B10ALDH1A1KMT2A
SCHEMBL4260569 0.81 CXCR5 (0.39) ACHENLRP3OPRK1HSD17B10ALDH1A1
SCHEMBL4258057 0.81 ACHE (0.44) ACHENLRP3OPRK1HSD17B10ALDH1A1
SCHEMBL7678090 0.81 CXCR5 (0.44) ACHENLRP3HSD17B10ALDH1A1KMT2A
SCHEMBL30995642 0.80 AKR1C3 (0.44) HSD17B10ALDH1A1KMT2AKDM4EHPGD
SCHEMBL19123318 0.80 AKR1C3 (0.44) HSD17B10ALDH1A1KMT2AKDM4EHPGD
SCHEMBL22859030 0.78 GRIA1 (0.51) OPRK1ALDH1A1KMT2AKDM4E
SCHEMBL3944054 0.78 MAPT (0.41) OPRK1HSD17B10ALDH1A1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024126650-A1 NOVEL BICYCLIC-CARBOXAMIDE COMPOUNDS USEFUL AS PESTICIDES SYNGENTA CROP PROTECTION AG (CH) 2024-06-20 WO disclosed
US-10752604-B2 C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same Je II Pharmaceutical Co., Ltd. (KR) 2020-08-25 US disclosed
US-10752604-B2 C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same Je II Pharmaceutical Co., Ltd. (KR) 2020-08-25 US disclosed
EP-3404033-B1 C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME JEIL PHARMACEUTICAL CO LTD (KR) 2020-08-05 EP disclosed
EP-3404033-B1 C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME JEIL PHARMACEUTICAL CO LTD (KR) 2020-08-05 EP disclosed
US-20190002425-A1 C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same JE IL PHARMACEUTICAL CO., LTD. (KR) 2019-01-03 US disclosed
US-20190002425-A1 C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same JE IL PHARMACEUTICAL CO., LTD. (KR) 2019-01-03 US disclosed
EP-3404033-A1 C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Jeil Pharmaceutical Co., Ltd. (KR) 2018-11-21 EP disclosed
WO-2017119700-A1 C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 제일약품주식회사 2017-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002425-A1 C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same SLC5A2, SLC5A1, UGGT1 ACHE 3857/4885NLRP3 292/4885OPRK1 3953/4885
US-10752604-B2 C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same SLC5A2, SLC5A1, UGGT1 ACHE 3857/4885NLRP3 292/4885OPRK1 3953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.